#1ORTHOFIX®™ Improving patient mobility through innovation#2Forward-Looking Statements and Non-GAAP Financial Measures Except for historical information contained herein, the statements made in this presentation constitute forward-looking statements that involve certain risks and uncertainties. These forward-looking statements are based on our beliefs and expectations as of August 5, 2022, and we do not undertake any obligation to revise or update such forward looking statements, which speak only as of such date. Certain factors may cause actual results to differ materially from those contained in the forward-looking statements, including those risks detailed under the heading Risk Factors in our Form 10-K for the year ended December 31, 2021, and Form 10-Q for the quarter ended June 30, 2022 each of which are on file at the Securities and Exchange Commission (SEC), as well as other reports we file with the SEC in the future. Orthofix may use certain non-GAAP financial measures in its presentations. Orthofix may also use non-GAAP financial measures as supplemental measures of performance and believes these measures can provide useful information to investors in evaluating our operations, period over period. However, non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation or as a substitute for Orthofix's financial results prepared in accordance with GAAP. In addition, investors should note that any non-GAAP financial measures Orthofix uses may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as that of other companies. Investors can find reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures in our earnings press releases. ORTHOFIX® | 2#3ABOUT ORTHOFIX We are a global medical device and biologics company with a spine and orthopedics focus. Our mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. - Helen PhysioStim Patient#4Transformational Leadership Management team with industry leading experience Jon Serbousek President and Chief Executive Officer Doug Rice Chief Financial Officer Kim Elting President, Global Orthopedics and Chief Legal and Development Officer Kevin Kenny President, Global Spine Ehab Esmail Senior Vice President, Quality, Regulatory and Clinical Affairs Roberto Donadello Senior Vice President, Global Operations Dalles Stiles Senior Vice President, Strategy Suzanne Armstrong Vice President, Human Resources ORTHOFIX® 4#5Orthofix Evolution ● ● OUR FOUNDATION 40+ years in operation Spine and specialty orthopedic solutions Rich clinical history ● ● Experienced leadership • Differentiated pipeline • Established global ● footprint Strong balance sheet ORTHOFIX TODAY Delivering and investing in innovation ● ● ● MOVING FORWARD Sustainable high-single-digit growth Taking market share by investing and building on our core strengths Accelerating R&D, strategic partnerships, and disciplined M&A Procedural solutions partner of choice ORTHOFIX® 5#6MARKET & PORTFOLIO - Randy Firefighter and M6-C Artificial Cervical Disc Patient Fire Service int FIR 403#7Orthofix Core Strengths & Synergies Delivering best-in-class spine and focused orthopedic solutions SPINAL IMPLANTS Motion Preservation Spine Fixation BIOLOGICS & REGENERATIVE TECHNOLOGIES Bone Growth Therapies Biologic Solutions ORTHOPEDICS Limb Reconstruction Deformity Correction ORTHOFIX 7#8Spinal Implants: Focused Execution Innovative artificial cervical disc and comprehensive spine fixation portfolio ● ● MOTION PRESERVATION 60,000+ M6-C™ artificial cervical discs implanted over the span of 16+ years Differentiated design to mimic natural disc Future opportunity to expand market $800 million U.S. market opportunity ● ● SPINE FIXATION Comprehensive interbody offering (PEEK, PTC, 3D-Printed Titanium, and expandable) Pipeline of competitive lumbar offerings $9.0 billion global market opportunity ORTHOFIX® 8#9Orthopedics: Limb Reconstruction & Deformity Correction Innovator in focused surgical specialties ● ● ● PEDIATRIC Comprehensive deformity correction portfolio History of cutting-edge pediatric solutions External and internal limb lengthening $800 million market opportunity 160 MM ID 160 MM IDO REF 882160 REF 2160 CE 2 ● CHARCOT FOOT Adult diabetic deformity correction solutions Calcaneal fractures and ankle fusions Hexapod ring fixation system $300 million market opportunity POST-TRAUMATIC Complex limb reconstruction Specialty frame innovator $1.0 billion market opportunity ORTHOFIX® 9#10Biologics & Regenerative Technologies Market-leading applications for spine and orthopedic patients BONE GROWTH THERAPIES - NONSURGICAL #1 prescribed bone growth stimulator in U.S. Proven Pulsed Electromagnetic Field (PEMF) technology ● ● ● Pipeline of Low Intensity Pulsed Ultrasound (LIPUS) technology Only FDA-approved cervical treatment indication $600 million market opportunity BIOLOGIC THERAPIES - SURGICAL #1 cellular allograft market share in spine Exclusive partnership with MTF Biologics Expanded portfolio of synthetic solutions $2.1 billion market opportunity ● ● ORTHOFIX 10#11INVESTING FOR THE FUTURE - Jennifer Spine Fixation Patient#12Strategic Investment to Accelerate Sustainable Growth PRODUCT INNOVATION & DIFFERENTIATION Creating consistent cadence of launches with high velocity innovation cycle Partnering with surgeons to deliver differentiated solutions Acquiring assets within focused verticals that add value Investing in strategic clinical and regulatory initiatives ● ● ● ● COMMERCIAL CHANNEL Developing more dedicated strategic sales partners Expanding distribution with investments in direct and indirect channels ● ● ● Leveraging untapped synergies among all OFIX product categories and sales channels AW Q'Shaun Orthopedics Patient ORTHOFIX 12#13Accelerating Innovation for Value Creation IGEA N. America Bone Growth Portfolio Fitbone™ US Pediatric Clearance 2021 Forza™ 3D Ti TLIF/PLIF Spacer System Opus™ Mg Set Synthetic Biologic Construx™ Mini 3D Ti Spacer System ● Inorganic Acquisition/Licensing Organic Development FiberFuse™ Strip M6-C™ Two-Level IDE Study Enrolled 1,000th U.S. M6-C Surgeon Trained nView enabling technology investment and co-development Opus BA™ Synthetic Bioactive Bone Graft 2022 MTF Biologics Exclusive Partnership Extension TrueLok™ EVO Ring Fixation System CGBio NovosisTM rhBMP-2 recombinant bone growth protein Fitbone partnership with Lima Orthopedics PMA clearance and launch AccelStim™ bone growth stimulator Virtuos™ Lyograft Galaxy Fixation Gemini™ System Legacy™ DBM demineralized bone matrix ORTHOFIX 13#14● ● ● Orthofix Growth Drivers: Near Term. Meaningful opportunities to grow within current significant markets M6-C DISC Attracting new users Comprehensive training program Collecting clinical data $800 million market opportunity ● ● FITBONE Strong early adoption Only internal limb lengthener with adult & pediatric FDA approval Recently performed first U.S. pediatric case $600 million market opportunity ● ● ● INTERBODIES Comprehensive interbody offering (PEEK, PTC, 3D- Printed Ti, and Expandable) Accelerating adoption Innovative new product introductions $1.6 billion market opportunity ● ● ● ● ● BIOLOGICS Building a robust portfolio Leveraging MTF Biologics partnership and portfolio: TrinityTM, VirtuosTM, Fiberfuse™ and Legacy™ Introduced differentiated synthetic solutions Driving incremental pull-through $2.1 billion market opportunity ● ● ACCELSTIM Ultrasound technology Expands BGT nonunion fracture portfolio Provides new fresh fracture indication Doubles Orthofix long bone market opportunity $250 million market opportunity ORTHOFXxX ORTHOFIX 14#15● ● ● Orthofix Growth Drivers: Future Notable growth opportunities through new indications and procedural solutions LONG TERM ASC SOLUTIONS Neo Medical partnership single use sterile instruments Cervical platform Patient-centric solutions $800 million market opportunity MID-TERM PEDIATRICS TrueLokTM expansion through radiolucent rings and struts Comprehensive pediatric plating system $800 million market opportunity ● ● FITBONE Trochanteric nail system for U.S. pediatric use Bone transport for trauma Expanded size offering $600 million market opportunity ● ● ● RCSTIM Rotator Cuff IDE clinical trial under way Entry into soft tissue repair First of its kind therapy Large un-served market ● CGBIO Conduct IDE clinical trials for U.S. FDA premarket approval Commercialize Novosis™ rhBMP-2 growth factor in the U.S. and Canada $650 million market opportunity NOVOSIS™ Recombinant una Morphoge P rhBMP-2 ● ● ● FITSPINE Early intervention growth rod Pediatric / adolescent scoliosis Limited competition Further differentiates pediatric portfolio $400 million market opportunity ORTHOFIX 15#16Commercial Channel Transforming our sales channel to realize synergies and sustained growth FOCUS ON MORE STRATEGIC DEDICATED SALES CHANNEL PARTNERS ● ● ● Selling multiple OFIX product lines Focused on expanding scale and stability Agnostic to model: agents, distributors, or direct reps MAXIMIZE BUSINESS COLLABORATIONS BETWEEN SPINE AND ORTHOPEDICS Cross-selling biologics & regenerative portfolio Utilizing strategic partners Committing resources to pediatric surgical training and education ● ● ● ORTHOFIX 16#17FINANCIAL OVERVIEW - Laura Wilkinson Three-Time Olympian and Orthofix Spine Patient 0008 X1NOTAS#182021 Revenue Mix SPINAL IMPLANTS Spine Fixation Motion Preservation 25% ● 23% $464M 14% YoY Growth 52% BIOLOGICS & REGENERATIVE TECHNOLOGIES Bone Growth Therapies - clinical Biologic Therapies - surgical LIMB RECONSTRUCTION & DEFORMITY CORRECTION Pediatric Charcot Foot ● ● ● Post-Traumatic REVENUE BY GEOGRAPHY 22% U.S. 78% International ORTHOFIX 18#19Quarterly Highlights ● SECOND QUARTER 2022 $118 million in net sales, flat on a constant currency basis versus the prior year Global Orthopedics net sales growth of 11% on a constant currency basis driven by new products and channel expansion Executed partnership with CGBio to commercialize NovosisTM rhBMP-2 growth factor in the United States and Canada Limited launch of VirtuosTM Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute $121 M ● 63% Q2 21 $112 M 1% Q3 21 REVENUE $125 M 7% Q4 21 $106 M 2% Q1 22 $118 M 0% Q2 22 Percentages represent sales growth in constant currency vs. prior year Quarterly results are impacted by COVID and seasonality ORTHOFIX 19#20Financial Overview $460 M 2019 REVENUE $407 M 2020 $464 M 2021 1% CC $460 M* * Midpoint of August 5, 2022 full year guidance 2022 F Gross Margin Adj. EBITDA Margin Cash & Equivalents Long-Term Debt TTM 74% 10% June 30, 2022 $60 million $0 FY 22 Guidance 74-75% 12%* ORTHOFIX®™ 20#21Investment Highlights Taking market share by investing and building on core strengths Near-term momentum building to sustainable high-single-digit revenue growth Strong balance sheet and ability to invest organically and inorganically Innovative and differentiated products and surgical solutions Strategic sales channels with increased surgeon-user growth Focused investments to drive operational excellence Attractive margin profile Janus Tental Soom Janu Fenestrated ORTHOFIX® 21 STERIS#22Orthofix (NASDAQ:OFIX) ANALYST COVERAGE JMP Securities Ladenburg Thalmann & Co Sidoti & Company Stifel IR Contact: Alexa Huerta, Senior Director of IR 214-937-3190 [email protected] David Turkaly Jeffrey Cohen Jim Sidoti Mathew Blackman INCO DORTHOFIX j the MOVE. 22